liu.seSök publikationer i DiVA
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Comparison of the mucosal adjuvant Endocine™ with two well-known adjuvants: cholera toxin and alum
Linköpings universitet, Institutionen för klinisk och experimentell medicin, Avdelningen för mikrobiologi och molekylär medicin. Linköpings universitet, Hälsouniversitetet.
Advanced Medical Research Laboratory, Mitsubishi Tanabe Pharma Corporation, Japan.
Advanced Medical Research Laboratory, Mitsubishi Tanabe Pharma Corporation, Japan.
Advanced Medical Research Laboratory, Mitsubishi Tanabe Pharma Corporation, Japan.
Visa övriga samt affilieringar
2015 (Engelska)Ingår i: Jacobs Journal of Vaccine and Vaccination, ISSN 2381-2664, Vol. 1, nr 1, artikel-id 006Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

To enable efficient mucosal vaccination with split or subunit antigens, an adjuvant is often needed. To date, no mucosal adjuvants are approved for human use, however, there are a variety of mucosal adjuvants in development, including the liposome-based adjuvant Endocine™. The aim of this study was to evaluate split influenza antigens together with Endocine™ and in order to assess the potency of Endocine™, the induction of humoral immune responses were compared to those following influenza vaccination with cholera toxin (CT) or aluminum salt (alum). We show that Endocine™ significantly enhances influenza-specific immune responses in intranasally immunized mice compared to nonadjuvanted vaccine. Furthermore, vaccines adjuvanted with Endocine™ evoked comparable serum IgG and virus neutralizing (VN) antibody titers as nasal vaccines adjuvanted with CT. Compared to parenteral vaccination with alum, Endocine™ triggered significantly higher mucosal and serum IgA titers, and similar VN titers. Taken together, these results support further development of Endocine™ as a mucosal adjuvant and as part of a nasal influenza vaccine candidate.

Ort, förlag, år, upplaga, sidor
Jacobs Publishers , 2015. Vol. 1, nr 1, artikel-id 006
Nyckelord [en]
Mucosal adjuvant; nasal immunization; vaccine; Endocine; influenza; neutralizing antibodies
Nationell ämneskategori
Klinisk laboratoriemedicin Cell- och molekylärbiologi
Identifikatorer
URN: urn:nbn:se:liu:diva-117979OAI: oai:DiVA.org:liu-117979DiVA, id: diva2:812606
Tillgänglig från: 2015-05-19 Skapad: 2015-05-19 Senast uppdaterad: 2018-01-11Bibliografiskt granskad
Ingår i avhandling
1. Nasal vaccination using novel mucosal adjuvants: with main focus on influenza A virus
Öppna denna publikation i ny flik eller fönster >>Nasal vaccination using novel mucosal adjuvants: with main focus on influenza A virus
2015 (Engelska)Doktorsavhandling, sammanläggning (Övrigt vetenskapligt)
Abstract [en]

Influenza viruses have sporadically caused pandemics during the last century, with the most severe occurring in 1918 when the “Spanish flu”, an A/H1N1 influenza virus, passed around the globe killing about 20-100 million people. Today 250 000-500 000 deaths occur annually due to influenza virus or secondary infection after influenza, e.g. pneumonia. Influenza viruses cause severe infections in susceptible age groups like children and elderly and in individuals with impaired immune response due to other medical conditions. The best way to prevent an influenza epidemic is by vaccination. Since the 1950´s we have vaccines against seasonal flu, but vaccine efficacy is not 100 % and there is a need to develop better and more effective vaccines, especially for the risk groups. Since the virus enters the host through the nasal cavity, nasal vaccination is a good approach. By stimulating a mucosal immune response already in the nasal cavity, the goal with nasal vaccination is to stop the virus before it enters the host. Nasal vaccination also reduces the risk of transmission of blood-borne diseases, and is less painful and easier to administer, compared to injectable vaccines.

In order to be able to use less immunogenic antigens, like split and subunit antigens, as nasal vaccine components, an adjuvant is needed to enhance the immune response. At the moment there is no licensed mucosal adjuvant for human use. Several studies are ongoing, but it is a complicated and long way to reach the market. In this thesis nasal vaccination with influenza antigen together with the mucosal adjuvant Endocine™ and other mucosal adjuvants has been evaluated. The Endocine™ adjuvant has been shown to be safe and well tolerated in clinical trials. Depending on the pathogen of interest, different approaches are necessary. For HIV, DNA-vaccination has been evaluated together with a plasmid encoding Salmonella typhimurium flagellin C and the mucosal adjuvant N3. The results found in paper I-IV show that by adding adjuvant to the antigen enhances the protective immune response towards the antigen. Enhanced systemic, mucosal and cell-mediated immunity were observed. Hopefully in the future these adjuvants evaluated in this thesis, will be used in vaccines for humans.

Ort, förlag, år, upplaga, sidor
Linköping: Linköping University Electronic Press, 2015. s. 57
Serie
Linköping University Medical Dissertations, ISSN 0345-0082 ; 1460
Nationell ämneskategori
Biokemi och molekylärbiologi Immunologi inom det medicinska området
Identifikatorer
urn:nbn:se:liu:diva-117981 (URN)10.3384/diss.diva-117981 (DOI)978-91-7519-060-0 (ISBN)
Disputation
2015-05-28, Eken, Campus US, Linköping, 09:00 (Svenska)
Opponent
Handledare
Tillgänglig från: 2015-05-19 Skapad: 2015-05-19 Senast uppdaterad: 2019-11-15Bibliografiskt granskad

Open Access i DiVA

fulltext(1114 kB)230 nedladdningar
Filinformation
Filnamn FULLTEXT01.pdfFilstorlek 1114 kBChecksumma SHA-512
163da4137dc24fe71bd47745bfe47e51f2b4a05dca0bf10ca8453df28c41ffe463aa1dd6f87ba40eb530507e33dd21cbb2a9dac5ad2b957d49474cea434891f1
Typ fulltextMimetyp application/pdf

Övriga länkar

Link to full text

Personposter BETA

Falkeborn, TinaHinkula, Jorma

Sök vidare i DiVA

Av författaren/redaktören
Falkeborn, TinaHinkula, Jorma
Av organisationen
Avdelningen för mikrobiologi och molekylär medicinHälsouniversitetet
Klinisk laboratoriemedicinCell- och molekylärbiologi

Sök vidare utanför DiVA

GoogleGoogle Scholar
Totalt: 230 nedladdningar
Antalet nedladdningar är summan av nedladdningar för alla fulltexter. Det kan inkludera t.ex tidigare versioner som nu inte längre är tillgängliga.

urn-nbn

Altmetricpoäng

urn-nbn
Totalt: 433 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf